Compile Data Set for Download or QSAR
Report error Found 110 Enz. Inhib. hit(s) with Target = 'Neprilysin/Angiotensin-converting enzyme'
TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582636(US11547687, Compound 21a)
Affinity DataIC50: 5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034868((2S,4R)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50: 5nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582640(US11547687, Compound 21d)
Affinity DataIC50: 27nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034865((2S,4S)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50: 27nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582641(US11547687, Compound 21e)
Affinity DataIC50: 90nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM617417(US20230285340, Compound 21e)
Affinity DataIC50: 90nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582635(US11547687, Compound 21g)
Affinity DataIC50: 92nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034843((2R,4S)-5-Biphenyl-4-yl-4-(2-carboxy-acetylamino)-...)
Affinity DataIC50: 92nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582637(US11547687, Compound 21b)
Affinity DataIC50: 190nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034842((2R,4S)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50: 190nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582643(US11547687, Compound 21f)
Affinity DataIC50: 324nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034857((2R,4S)-5-Biphenyl-4-yl-4-(5-carboxy-pentanoylamin...)
Affinity DataIC50: 324nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582639(US11547687, Compound 21c)
Affinity DataIC50: 700nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034846((2R,4R)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50: 700nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US11547687, Example 2A | US11547687, Compound Exam...)
Affinity DataKi:  0.200nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582848(US11547687, Comparative Compound J | US20230285340...)
Affinity DataKi:  0.316nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582849(US11547687, Comparative Compound K)
Affinity DataKi:  0.501nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298305(US11547687, Compound Example 5A | US10123984, Exam...)
Affinity DataKi:  0.631nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582645(US11547687, Example 5-13)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US11547687, Example 2A | US11547687, Compound Exam...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582648(US11547687, Example 5-14)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582655(US11547687, Example 5-15)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582656(US11547687, Example 5-17)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298305(US11547687, Compound Example 5A | US10123984, Exam...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298286(US11547687, Example 2F | US10744104, Example 2F | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298288(US11547687, Example 2H | US10123984, Example 2H | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298306(US10123984, Example 7B | US11547687, Example 7B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582669(US11547687, Example 8-2)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458409(US10744104, Example 7B | US11547687, Example 8-3 |...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298291(US10123984, Example 2N | US11547687, Example 2N | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582685(US11547687, Example 11-2)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298292(US10123984, Example 2T | US10744104, Example 2T | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298293(US11547687, Example 2U | US10744104, Example 2U | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298294(US11547687, Example 2V | US10744104, Example 2V | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298295(US20230285340, Example 3A | US10123984, Example 3D...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458421(US10744104, Example 14A | US11547687, Example 14A ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582706(US11547687, Example 3D)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582710(US11547687, Example 5-1)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582718(US11547687, Example 5-5)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582719(US11547687, Example 5-9)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582844(US11547687, Comparative Compound G | US20230285340...)
Affinity DataKi:  1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US11547687, Example 2A | US11547687, Compound Exam...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298286(US11547687, Example 2F | US10744104, Example 2F | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298288(US11547687, Example 2H | US10123984, Example 2H | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298291(US10123984, Example 2N | US11547687, Example 2N | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298292(US10123984, Example 2T | US10744104, Example 2T | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298293(US11547687, Example 2U | US10744104, Example 2U | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298294(US11547687, Example 2V | US10744104, Example 2V | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298295(US20230285340, Example 3A | US10123984, Example 3D...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458399(US10744104, Example 3D | US20230285340, Example 3D)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 110 total ) | Next | Last >>
Jump to: